Wedbush Reiterates Outperform Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Wedbush restated their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report report published on Friday, Marketbeat reports. Wedbush currently has a $181.00 price target on the biotechnology company’s stock.

ASND has been the topic of several other reports. StockNews.com cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Jefferies Financial Group lifted their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. cut their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Oppenheimer reiterated an “outperform” rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Finally, Citigroup lifted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $122.00 on Friday. The stock’s 50 day simple moving average is $132.40 and its two-hundred day simple moving average is $132.47. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of -15.10 and a beta of 0.66. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, analysts predict that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the company. Groupama Asset Managment purchased a new position in Ascendis Pharma A/S in the 3rd quarter worth approximately $60,000. Signaturefd LLC raised its holdings in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the last quarter. Bessemer Group Inc. raised its holdings in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares during the last quarter. Searle & CO. purchased a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $205,000. Finally, Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.